1. A rohitukine derivative IIIM‐290 induces p53 dependent mitochondrial apoptosis in acute lymphoblastic leukemia cells
- Author
-
Abubakar Wani, Dilip M. Mondhe, Mubashir J. Mintoo, Sameer U. Khan, Sandip B. Bharate, Deendyal Bhurta, Fayaz Malik, and Sumera Banu Malik
- Subjects
Cancer Research ,Programmed cell death ,Poly ADP ribose polymerase ,Apoptosis ,Mice ,Piperidines ,Downregulation and upregulation ,In vivo ,Cell Line, Tumor ,Animals ,Humans ,Molecular Biology ,chemistry.chemical_classification ,Reactive oxygen species ,biology ,Cytochrome c ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Cell cycle ,Antineoplastic Agents, Phytogenic ,Xenograft Model Antitumor Assays ,Mitochondria ,Gene Expression Regulation, Neoplastic ,Disease Models, Animal ,chemistry ,Chromones ,biology.protein ,Cancer research ,Tumor Suppressor Protein p53 ,Apoptosis Regulatory Proteins - Abstract
Rohitukine, a chromone alkaloid extracted from Dysoxylum binectariferum, has a propitious anticancer activity. Our previous study shows that a new Rohitukine derivative IIIM-290 restricts the growth of pancreatic cancer in vivo and in vitro. In the present findings, we report the mechanism of cell death induced by IIIM-290 in MOLT-4 cells (acute lymphoblastic leukemia) and its anticancer potential against various murine leukemic tumor models in vivo. We found that IIIM-290 induced apoptosis through upregulation of different apoptotic proteins like PUMA, BAX, cytochrome c, cleaved (active) caspase-3, and cleaved PARP in MOLT-4 cells. Moreover, IIIM-290 abated mitochondrial membrane potential, elevated calcium levels, reactive oxygen species, and arrested growth of MOLT-4 cells in the synthesis (S) phase of the cell cycle. Interestingly, the elevation in proapoptotic markers was p53 dependent-the silencing of p53 abrogated apoptosis (programmed cell death) triggered by IIIM-290 in MOLT-4 cells. Furthermore, IIIM-290 significantly enhanced the survival of animals with P388 and L1210 leukemia. Thus, our results put IIIM-290 as a potential candidate for the anticancer lead.
- Published
- 2021
- Full Text
- View/download PDF